In addition, the reduction in endogenous PLOD2 levels in L1-expressing CRC cells, by the stable expression of shRNA to PLOD2, was also effective in blocking the increase in tumorigenic capacity conferred by L1 (Figure 3A,B, L1 + shPLOD2 cl2 and cl3, compare to L1). Here, PLOD2 is linked to colorectal carcinoma.